Clinical trials: Hepatobiliary Disorders
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Hepatitis C, Chronic, Liver Diseases
The Patient-Reported Outcomes Project of HCV-TARGET
The PROP UP research study is funded by The Patient Centered Outcomes Research Institute (PCORI). PROP UP is a multi-centered prospective observational study that will evaluate all-oral treatment regimens for chronic hepatitis C…
- Trial name
- PROP-UP (NCT02601820)
- Where
- 11 sites in United States
- Volunteers
- 1,601 people
- Sponsor
- University of North Carolina, Chapel Hill
Metastatic Biliary Tract Carcinoma
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Based on the facts of multiple pathways involvement in cholangiocarcinoma tumor genesis, including EGFR, Ras, Raf, VEGFR, and PDGFR, with evidence of overexpression of these proteins associated with tumor stage, prognosis and…
- Trial name
- NCT02053376
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Nathan Bahary, MD
Non-Alcoholic Fatty Liver Disease
Investigation of Synbiotic Treatment in NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a liver condition in which fat builds up in the liver not caused by alcohol. The liver is an organ that is not designed to build up fat.
- Trial name
- INSYTE (NCT01680640)
- Testing
- Synbiotic, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Non-alcoholic Fatty Liver Disease
6-week Safety and PD Study in Adults With NAFLD
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH…
- Trial name
- NCT03256526
- Testing
- PF-06835919 Low Dose, PF-06835919 High Dose
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Non Alcoholic Fatty Liver Disease
The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease
The purpose of this study is to examine whether CPAP therapy can reduce or eliminate hepatic fat accumulation in obese children and adolescents.
- Trial name
- NCT02134522
- Testing
- Continuous positive airway pressure (CPAP).
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00535145
- Testing
- Treatment as usual (TAU), Paliperidone ER
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of…
- Trial name
- NCT00845845
- Testing
- Omega-3-acid ethyl esters (Lovaza)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
NASH - Nonalcoholic Steatohepatitis
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in…
- Trial name
- NCT05415722
- Testing
- TERN-501, TERN-101
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC].
- Conditions
- Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
- Trial name
- RISE (NCT04729751)
- Testing
- Maralixibat
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 27 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Liver Transplant, Liver Steatosis
Controlled Attenuation Parameter (CAP) in Liver Allografts
The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze…
- Conditions
- Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function
- Trial name
- NCT02798861
- Testing
- Fibroscan 402/530
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Andres Duarte-Rojo
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
- Trial name
- NCT02605616
- Testing
- AZ compound
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Alabama at Birmingham
Nonalcoholic Fatty Liver Disease
Role of Exenatide in NASH-a Pilot Study
We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.
- Trial name
- NAFLD (NCT00650546)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
NASH - Nonalcoholic Steatohepatitis
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men with NASH.
- Trial name
- NCT04685993
- Testing
- LPCN 1144
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lipocine Inc.
Cirrhosis, Portal Hypertension
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this…
- Conditions
- Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
- Trial name
- ENCORE-PH (NCT02960204)
- Testing
- Emricasan
- Where
- 37 sites in United States, Germany and 1 more
- Volunteers
- 263 people
- Sponsor
- Histogen
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH…
- Trial name
- NCT01244503
- Testing
- Sodium Octanoate Breath Test
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Virginia Commonwealth University
Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
- Trial name
- SYNERGY-NASH (NCT04166773)
- Testing
- Tirzepatide
- Where
- 112 sites in United States, Belgium and 8 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Liver Diseases
Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy…
- Trial name
- BLOCS (NCT03245580)
- Testing
- Core Liver Biopsy
- Where
- 7 sites in United States
- Volunteers
- 153 people
- Sponsor
- Parkview Health